Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Arrowhead Pharmaceuticals (ARWR): Can the Stock Reach a +120% Move to the $105 Target?

Arrowhead Pharmaceuticals (ARWR): Can the Stock Reach a +120% Move to the $105 Target?

Key Takeaways

  • The central target of $105 is the arithmetic mean of roughly a dozen current, attributable analyst price targets reviewed for this analysis, rounded to a clean level.
  • The latest verified share price is about $47.78, meaning the stock would need to rise roughly 120% to reach the target — a very large move by any standard.
  • Individual targets are widely dispersed, from roughly $46 (Bernstein) at the low end to $126 (Piper Sandler) at the high end, reflecting deep disagreement about the commercial opportunity.
  • The strongest support comes from REDEMPLO (plozasiran), the first approved RNAi therapy for familial chylomicronemia syndrome (FCS), and its planned expansion into the far larger severe hypertriglyceridemia (sHTG) market.
  • The biggest risks are weak current revenue, ongoing losses, an uncertain payer-conversion path, a blood-sugar safety signal, and competition from Ionis Pharmaceuticals' olezarsen.
  • For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the additional pages covering each topic.
  • Explore Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.

Analyst Price Targets and Consensus View

Wall Street coverage of ARWR remains broadly constructive, with most major firms carrying a Buy or Overweight rating and independent aggregators reporting a "Strong Buy" consensus. The individual targets, however, tell a more nuanced story. Averaging the current, attributable targets from firms including Piper Sandler ($126), B. Riley Securities ($123), H.C. Wainwright ($120), UBS ($109), Morgan Stanley ($106), Stifel ($96), Bank of America ($93), Chardan Capital ($90), RBC Capital ($87), and Goldman Sachs ($85, Hold) produces a mean near $105, which we use as the central target. Bernstein's more cautious $46 Hold target sits well below that cluster, and the full range from roughly $46 to $126 is unusually wide. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent revisions reflect a split in confidence. Morgan Stanley lowered its target to $106 from $120, and Stifel trimmed to $96 from $104, while UBS initiated coverage with a Buy and a $109 target and Piper Sandler and B. Riley maintained targets above $120. Bullish analysts emphasize the commercial de-risking of REDEMPLO and the scale of the sHTG opportunity; cautious analysts point to thin current revenue, heavy spending, and execution risk in commercial build-out.

Current Market Position and Path Toward the Target

At approximately $47.78, ARWR sits near the middle of its 52-week range of roughly $37 to $95, with a market capitalization around $6.8 billion. Reaching $105 would require a gain of about 120% — a very large move that would essentially require the market to re-rate the stock from a pre-commercial RNAi developer to a credible, revenue-generating cardiometabolic franchise.

The path runs through REDEMPLO. The drug is approved for FCS in multiple markets, and the company has filed a supplemental new drug application (sNDA) for sHTG under the FDA's STAR pilot program, targeting a potential U.S. launch in the second quarter of 2027. Late-stage SHASTA-3 and SHASTA-4 data showed median triglyceride reductions of 79% and 81% and a 78% reduction in acute pancreatitis events. Yet fiscal 2026 results underscore the gap between promise and profit: revenue of about $450.8 million was down 46% year over year, and the company posted a net loss of roughly $724 million, or $5.11 per share, missing consensus.

What Could Support a Move Toward the Target

  • Commercial momentum: New-to-brand REDEMPLO prescriptions grew 63% quarter over quarter, with cumulative scripts exceeding 1,250 by early November and formulary coverage surpassing 160 million U.S. lives.
  • Large market expansion: A successful sHTG launch would open a patient population orders of magnitude larger than the rare FCS niche, with hard-outcome data supporting the case.
  • Expedited review: Entry into the FDA's STAR pilot provides a six-month priority review framework, potentially accelerating the sHTG timeline.
  • Strengthened balance sheet: Cash resources near $1.19 billion and a refinanced $400 million term loan at a sharply lower rate extend the runway into the launch phase.
  • Platform optionality: Programs such as ARO-DIMER-PA and ARO-MAPT add long-term upside beyond the core lipid franchise.

What Could Prevent the Target From Being Reached

  • Revenue lag: Fiscal 2026 net product revenue was only about $6.6 million, and management has not provided revenue guidance, citing prescription-to-paid-shipment conversion as a "choke point."
  • Persistent losses: A near-billion-dollar expense base continues to outpace revenue, pressuring valuation.
  • Safety signal: Worsening blood-sugar control was reported in 14% of plozasiran patients versus 8.7% on placebo — a meaningful concern in a larger, less acutely ill sHTG population.
  • Competition: Ionis Pharmaceuticals' olezarsen competes in the same triglyceride-lowering space.
  • Regulatory and execution risk: sHTG approval is not guaranteed, and any delay would materially shift the timeline underpinning higher targets.

Technical Levels and Market Structure

ARWR has been range-bound after pulling back from its 52-week high near $95, with durable support in the mid-to-high $30s around its 52-week low of roughly $37. Resistance is layered: the psychological $50 level sits just overhead, followed by prior congestion near $60 and the larger supply zone approaching $95. Reaching $105 would require a sustained breakout above that prior high, implying a structural trend change rather than a routine recovery. The stock's decline after its fiscal-year earnings miss suggests technical momentum remains weak in the near term. From what I see, the AI Trend Prediction Engine helps highlight these key levels more clearly.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. Key items to watch include the FDA's PDUFA date for the sHTG supplement (expected in the weeks ahead), payer-coverage and prescription-conversion metrics each quarter, the pace of REDEMPLO revenue recognition, and any updates on the ARO-DIMER-PA and ARO-MAPT pipeline programs. Because the company is changing its fiscal year end from September 30 to December 31, investors should also note the timing of upcoming transition-period filings and earnings reports, as well as further analyst target revisions in either direction.

Using Tickeron AI Tools for Deeper Insights

In my view, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to complement traditional research on names like ARWR. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI-driven analysis. For a volatile stock, these signals can help identify momentum shifts and trend changes more efficiently than manual checks alone. Traders often use them to spot new opportunities, track positions, and stay ahead of developments. I find this approach particularly useful when reviewing clinical-stage biotechs where sentiment can shift quickly.

Final Assessment

The $105 central target for Arrowhead Pharmaceuticals represents the average of a wide range of analyst views, and it implies a roughly 120% advance from the current price near $47.78 — a very large move. The bull case rests on REDEMPLO's launch into severe hypertriglyceridemia, compelling late-stage efficacy data, and an expedited regulatory path. The bear case centers on minimal current revenue, deep losses, an uncertain conversion funnel, a diabetes-related safety signal, and fierce competition. The unusually wide $46-to-$126 analyst range reflects genuine uncertainty about how quickly clinical promise becomes commercial reality. Investors should watch the sHTG regulatory decision, payer coverage, and prescription conversion most closely, while treating the $105 figure as an analytical benchmark rather than a forecast. I'm watching this closely as the regulatory timeline unfolds.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARWR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ARWR in +2.47% Uptrend, rising for three consecutive days on October 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARWR advanced for three days, in 222 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

The 50-day moving average for ARWR moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ARWR entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.647) is normal, around the industry mean (3.592). P/E Ratio (-25.509) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Industry
Biotechnology
Address
177 E Colorado Boulevard
Phone
+1 626 304-3400
Employees
711
Web
https://www.arrowheadpharma.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.